Pharmacokinetics of drugs in pregnancy

Seminars in Perinatology

Volumn 39, Issue 7, 2015, Pages 512-519

  Feghali, Maisa ^a   Venkataramanan, Raman ^b,c   Caritis, Steve ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CAFFEINE; CEFAZOLIN; CLINDAMYCIN; DIAZEPAM; DIGOXIN; FLUOXETINE; GLIBENCLAMIDE; INDINAVIR; LITHIUM; METHADONE; MORPHINE; NIFEDIPINE; PROPRANOLOL; PRESCRIPTION DRUG;

DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; FETUS RISK; HUMAN; NONHUMAN; PHARMACOKINETIC PARAMETERS; PREGNANCY OUTCOME; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; ADULT; ATTITUDE TO HEALTH; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FETOMATERNAL TRANSFUSION; LEGISLATION AND JURISPRUDENCE; NEWBORN; ORGANIZATION AND MANAGEMENT; PREGNANCY; PRENATAL EXPOSURE; PREVENTION AND CONTROL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANT WOMEN; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTION DRUGS;

EID: 84945131769     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2015.08.003     Document Type: Review

References (85)

1. Chambers C.D., Polifka J.E., Friedman J.M. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther 2008, 83(1):181-183.
2. Mitchell A.A., Gilboa S.M., Werler M.M., et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011, 205(1):51.e51-51.e58.
3. Thomas S.H., Yates L.M. Prescribing without evidence-pregnancy. Br J Clin Pharmacol 2012, 74(4):691-697.
4. LZ B. Pharmacokinetics: absorption, distribution, and elimination. Basic and Clinical Pharmacology 1992, Conn: Appleton & Lange, East Norwalk. K. BG (Ed.).
5. Vasicka A., Lin T.J., Bright R.H. Peptic ulcer and pregnancy; review of hormonal relationships and a report of one case of massive gastrointestinal hemorrhage. Obstet Gynecol Surv 1957, 12(1):1-13.
6. Waldum H.L., Straume B.K., Lundgren R. Serum group I pepsinogens during pregnancy. Scand J Gastroenterol 1980, 15(1):61-63.
7. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J Infect Dis 1977, 136(3):370-376.
8. Philipson A., Stiernstedt G., Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet 1987, 12(2):136-144.
9. Qasqas S.A., McPherson C., Frishman W.H., Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol Rev 2004, 12(4):201-221.
10. Pirani B.B., Campbell D.M., MacGillivray I. Plasma volume in normal first pregnancy. J Obstet Gynaecol Br Commonw 1973, 80(10):884-887.
11. Cheung C.K., Lao T., Swaminathan R. Urinary excretion of some proteins and enzymes during normal pregnancy. Clin Chem 1989, 35(9):1978-1980.
12. Erman A., Neri A., Sharoni R., et al. Enhanced urinary albumin excretion after 35 weeks of gestation and during labour in normal pregnancy. Scand J Clin Lab Invest 1992, 52(5):409-413.
13. Hayashi M., Ueda Y., Hoshimoto K., et al. Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia. Am J Kidney Dis 2002, 39(2):392-400.
14. Murphy M.M., Scott J.M., McPartlin J.M., Fernandez-Ballart J.D. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution, or a decrease in albumin in a longitudinal study. Am J Clin Nutr 2002, 76(3):614-619.
15. Hebert M.F., Zheng S., Hays K., et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation 2013, 95(7):908-915.
16. Perucca E., Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet 1982, 7(4):336-352.
17. Brazier J.L., Ritter J., Berland M., Khenfer D., Faucon G. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther 1983, 6(5):315-322.
18. Hebert M.F., Easterling T.R., Kirby B., et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 2008, 84(2):248-253.
19. Hirt D., Treluyer J.M., Jullien V., et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother 2006, 50(6):2079-2086.
20. Villani P., Floridia M., Pirillo M.F., et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol 2006, 62(3):309-315.
21. Tracy T.S., Venkataramanan R., Glover D.D., Caritis S.N., National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Unit Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005, 192(2):633-639.
22. Carter B.L., Driscoll C.E., Smith G.D. Theophylline clearance during pregnancy. Obstet Gynecol 1986, 68(4):555-559.
23. Tsutsumi K., Kotegawa T., Matsuki S., et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther 2001, 70(2):121-125.
24. Grosso L.M., Bracken M.B. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol 2005, 15(6):460-466.
25. Pennell P.B., Newport D.J., Stowe Z.N., Helmers S.L., Montgomery J.Q., Henry T.R. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004, 62(2):292-295.
26. de Haan G.J., Edelbroek P., Segers J., et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004, 63(3):571-573.
27. Haas D.M., Quinney S.K., Clay J.M., et al. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol 2013, 30(4):275-281.
28. Bogen D.L., Perel J.M., Helsel J.C., et al. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. Psychopharmacology 2013, 225(2):441-451.
29. Zhao Y., Alshabi A.M., Caritis S., Venkataramanan R. Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes. Am J Obstet Gynecol 2014, 211(4):412.e411-412.e416.
30. Davison J.M., Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980, 18(2):152-161.
31. Chamberlain A., White S., Bawdon R., Thomas S., Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am J Obstet Gynecol 1993, 168(2):667-673.
32. Allegaert K., van Mieghem T., Verbesselt R., et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol 2009, 200(2):170.e171-170.e177.
33. Muller A.E., Mouton J.W., Oostvogel P.M., et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother 2010, 54(5):2175-2181.
34. Anderson G.D. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005, 44(10):989-1008.
35. Syme M.R., Paxton J.W., Keelan J.A. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004, 43(8):487-514.
36. Schou M., Amdisen A., Steenstrup O.R. Lithium and pregnancy. II. Hazards to women given lithium during pregnancy and delivery. Br Med J 1973, 2(5859):137-138.
37. Luxford A.M., Kellaway G.S. Pharmacokinetics of digoxin in pregnancy. Eur J Clin Pharmacol 1983, 25(1):117-121.
38. Hebert M.F., Carr D.B., Anderson G.D., et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 2005, 45(1):25-33.
39. St-Pierre M.V., Serrano M.A., Macias R.I., et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000, 279(4):R1495-R1503.
40. Ushijima K., Kimura A., Inokuchi T., et al. Placental transport of bile acids: analysis of bile acids in maternal serum and urine, umbilical cord blood, and amniotic fluid. Kurume Med J 2001, 48(2):87-91.
41. Enders A.C., Blankenship T.N. Comparative placental structure. Adv Drug Deliv Rev 1999, 38(1):3-15.
42. Nagashige M., Ushigome F., Koyabu N., et al. Basal membrane localization of MRP1 in human placental trophoblast. Placenta 2003, 24(10):951-958.
43. Mylona P., Hoyland J.A., Sibley C.P. Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: no evidence for complementary expression. Placenta 1999, 20(5-6):493-496.
44. Meyer Zu Schwabedissen H.E., Grube M., Heydrich B., et al. Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation. Am J Pathol 2005, 166(1):39-48.
45. Raggers R.J., van Helvoort A., Evers R., van Meer G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J Cell Sci 1999, 112(Pt 3):415-422.
46. Yeboah D., Sun M., Kingdom J., et al. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 2006, 84(12):1251-1258.
47. Lee Y.J., Kusuhara H., Jonker J.W., Schinkel A.H., Sugiyama Y. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther 2005, 312(1):44-52.
48. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38(7-8):802-832.
49. Robey R.W., To K.K., Polgar O., et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009, 61(1):3-13.
50. Polgar O., Robey R.W., Bates S.E. ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 2008, 4(1):1-15.
51. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55(1):3-29.
52. Doyle L.A., Yang W., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998, 95(26):15665-15670.
53. Sun M., Kingdom J., Baczyk D., Lye S.J., Matthews S.G., Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 2006, 27(6-7):602-609.
54. Gil S., Saura R., Forestier F., Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005, 26(2-3):268-270.
55. Mathias A.A., Hitti J., Unadkat J.D. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 2005, 289(4):R963-R969.
56. Meyer zu Schwabedissen H.E., Dreisbach A., Hammer E., et al. Direct mass spectrometric identification of ABCB1 (P-glycoprotein/MDR1) from the apical membrane fraction of human placenta using fourier transform ion cyclotron mass spectrometry. Pharmacogenet Genomics 2006, 16(6):385-389.
57. Evseenko D.A., Paxton J.W., Keelan J.A. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 2007, 35(4):595-601.
58. Coles L.D., Lee I.J., Voulalas P.J., Eddington N.D. Estradiol and progesterone-mediated regulation of P-gp in P-gp overexpressing cells (NCI-ADR-RES) and placental cells (JAR). Mol Pharm 2009, 6(6):1816-1825.
59. Petropoulos S., Gibb W., Matthews S.G. Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse. Placenta 2010, 31(9):803-810.
60. Petropoulos S., Gibb W., Matthews S.G. Glucocorticoid regulation of placental breast cancer resistance protein (Bcrp1) in the mouse. Reprod Sci 2011, 18(7):631-639.
61. Mason C.W., Buhimschi I.A., Buhimschi C.S., Dong Y., Weiner C.P., Swaan P.W. ATP-binding cassette transporter expression in human placenta as a function of pregnancy condition. Drug Metab Dispos 2011, 39(6):1000-1007.
62. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003, 305(1):197-204.
63. Evans J., Heron J., Francomb H., Oke S., Golding J. Cohort study of depressed mood during pregnancy and after childbirth. Br Med J 2001, 323(7307):257-260.
64. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015.
65. Tuccori M., Testi A., Antonioli L., et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009, 31(Pt 1):1426-1453.
66. Wu S.P., Shyu M.K., Liou H.H., Gau C.S., Lin C.J. Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 2004, 45(3):204-210.
67. Siu K.L., Lee W.H. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension. J Paediatr Child Health 2004, 40(3):152-153.
68. Pons R., De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J Child Neurol 1995, 10(suppl 2):S8-S24.
69. Tamai I., Ohashi R., Nezu J., et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998, 273(32):20378-20382.
70. --coupled active transport of carnitine by the amino acid transporter ATB(0,+) from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol 2001, 532(Pt 2):297-304.
71. Moses-Kolko E.L., Bogen D., Perel J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. J Am Med Assoc 2005, 293(19):2372-2383.
72. Nordeng H., Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 2005, 28(7):565-581.
73. Yeomans E.R., Gilstrap L.C. Physiologic changes in pregnancy and their impact on critical care. Crit Care Med 2005, 33(suppl 10):S256-S258.
74. Clark S.L., Cotton D.B., Lee W., et al. Central hemodynamic assessment of normal term pregnancy. Am J Obstet Gynecol 1989, 161(6 Pt 1):1439-1442.
75. Bonica J.J., McDonald J.S. Principles and Practice of Obstetric Analgesia and Anesthesia 1995, Williams & Wilkins, Baltimore, MD. 2nd ed.
76. Nakai A., Sekiya I., Oya A., Koshino T., Araki T. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet 2002, 266(1):25-29.
77. Hodge L.S., Tracy T.S. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 2007, 3(4):557-571.
78. Tamminga W.J., Wemer J., Oosterhuis B., et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999, 55(3):177-184.
79. Claessens A.J., Risler L.J., Eyal S., Shen D.D., Easterling T.R., Hebert M.F. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos 2010, 38(9):1393-1396.
80. McGready R., Stepniewska K., Seaton E., et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003, 59(7):553-557.
81. Aldridge A., Bailey J., Neims A.H. The disposition of caffeine during and after pregnancy. Semin Perinatol 1981, 5(4):310-314.
82. Harden C.L., Pennell P.B., Koppel B.S., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: report of the Quality Standards Subcommittee and therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50(5):1247-1255.
83. Harden C.L., Meador K.J., Pennell P.B., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50(5):1237-1246.
84. Harden C.L., Hopp J., Ting T.Y., et al. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50(5):1229-1236.
85. Reimers A., Helde G., Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005, 46(9):1414-1417.